Compare Iris Energy Limited (IREN) vs Novavax Inc (NVAX) Price & Performance

IREN stock trades at $35.15, down 9.15% in the last 24 hours, reflecting bearish technical signals despite strong analyst buy ratings. The company reported revenue of $501.02M in 2025 with a net income of $86.94M, but recent quarterly EPS misses and a projected net loss of -$703M for 2026 highlight profitability challenges. Key developments include a $9.7 billion deal with Microsoft and a strategic pivot from Bitcoin mining to AI cloud services, positioning IREN in the high-growth AI infrastructure sector.

The outlook for IREN is mixed: significant upside exists from analyst price targets averaging $81.00, driven by AI demand and contracted revenue, but risks include execution on massive capital expenditure, intense competition, and current negative profitability. Investors face high volatility amid transformative growth ambitions versus near-term financial strain.

Novavax (NVAX) trades at $12.41, up 10.61% today, with strong technical momentum and bullish moving average signals. The company shows mixed fundamentals with a low P/E of 3.14 and EV/EBITDA of 1.72, but negative net income margin of -59.87% and negative shareholder equity. Recent earnings beats and FDA approvals for updated COVID-19 vaccines provide near-term catalysts.

Investment outlook remains speculative with significant execution risks despite analyst optimism (74% buy ratings). The company's pivot to Matrix-M adjuvant licensing and partnership model offers growth potential, but negative cash flow and high debt levels pose substantial financial risk. Stock appears undervalued on some metrics but requires careful risk management.